Table 3.
Extent and intensity of FGFR3 Expression in different malignant cases about tumour grades and stages
| Carcinoma | Number of positive cases | Mean % of positive cells ± S.D. | Intensity of FGFR3 immunostaining | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Mild | Moderate | Marked | |||||||
| No | % | No | % | No | % | ||||
| Transitional cell carcinoma n=75 | 54 | 72% | 40.5±30 | 29 | 38.6% | 16 | 21.4% | 9 | 12% |
| Superficial Tumours (NMIBC)TCC n=45 | 40 | 88.8% | 52.4±26.2 | 18 | 40% | 15 | 33.3% | 7 | 15.6% |
| Muscle invasive in TCC n=30 | 14 | 46.7% | 22.6±28.5(a) | 11 | 78.5% | 1 | 7.2% | 2 | 14.2% |
| Low grade Tumors TCC n=28 | 26 | 92.8% | 58.5±22 | 9 | 32.2% | 11 | 39.2% | 6 | 21.4% |
| High Grade Tumors in TCC n=47 | 28 | 59.5% | 29.7±30.2(b) | 20 | 71.4% | 5 | 17.8% | 3 | 10.7% |
| Squamous cell carcinoma n=15 | 7 | 46.7% | 31.3±36 | 4 | 26.7% | 3 | 20% | 0 | 0 |
| Superficial Tumors (NMIBC) in scc n=0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Muscle invasive Tumors in scc n=15 | 7 | 46.7% | 31.3±36.8 | 4 | 26.7% | 3 | 20% | 0 | 0 |
| Low Grade SCC N=0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| High-Grade SCC N=15 | 7 | 46.7% | 31.3±36.8 | 4 | 26.7% | 3 | 20% | 0 | 0 |
(a)A significant difference between NMIBC and Invasive bladder cancer of TCC type; (b) Significant difference between low-grade tumours and high-grade tumours at p-value <0.05